acrolein has been researched along with ponalrestat in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hunsaker, LA; Kolb, NS; Vander Jagt, DL | 1 |
| Cao, D; Cao, Z; Chen, X; Huang, D; Huang, H; Wang, Y; Wang, Z; Zhang, X; Zhou, B | 1 |
2 other study(ies) available for acrolein and ponalrestat
| Article | Year |
|---|---|
Aldose reductase-catalyzed reduction of acrolein: implications in cyclophosphamide toxicity.
Topics: Acrolein; Aldehyde Reductase; Cyclophosphamide; Enzyme Activation; Humans; Imidazoles; Imidazolidines; Muscles; Oxidation-Reduction; Phthalazines; Substrate Specificity | 1994 |
Statil suppresses cancer cell growth and proliferation by the inhibition of tumor marker AKR1B10.
Topics: Acrolein; Aldehyde Reductase; Aldo-Keto Reductases; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Diclofenac; DNA Damage; Humans; Lung Neoplasms; Phthalazines | 2014 |